Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate

Academic Article

Abstract

  • Background: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youths treated with combination antiretroviral therapy (cART) containing or not containing TDF.
  • Authors

    Published In

  • Antiviral Therapy  Journal
  • Digital Object Identifier (doi)

    Author List

  • Havens PL; Hazra R; Stephensen CB; Kiser JJ; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR
  • Start Page

  • 613
  • End Page

  • 618
  • Volume

  • 19
  • Issue

  • 6